Patritumab deruxtecan shows meaningful clinical activity in heavily pretreated patients with metastatic breast cancer and ...

Phase III trial for KLU156 (ganaplacide/lumefantrine, or GanLum), meets primary endpoint of non-inferiority to standard of care Coartem® (artemether-lumefantrine) Demonstrates PCR-corrected cure rate ...

The robust 77.8% three-month CR rate observed in the UTOPIA trial is highly encouraging and reinforces the potential of UGN-103 to deliver meaningful benefits to patients,” said Liz Barrett, President ...

A light pulse redirects electrons in an ultrathin layered material, creating a stable new state without heat or damage and ...

Partial Response and 82.4% Disease Control Rate Observed in Interim Phase II Data SEONGNAM, South Korea, /PRNewswire/ -- On ...

First-in-class dendritic cell (DC) maturation agent Plinabulin drives immune re-sensitization in metastatic NSCLC patients ...

As the utilities industry transitions core systems to the cloud, many organizations are unprepared for the scale and ...

-- 63% complete response (CR) rate at any time (n=62); -- 56% CR rate at 3 months (n=62); -- 62% CR rate at 6 months (n=37), with 4 patients having successfully converted to CR post reinduction; and - ...

A bench of Justices Surya Kant and Joymalya Bagchi asked the poll panel to respond to the fresh petitions in two weeks.

Gaza: Efforts to move into the second phase of US President Donald Trump’s ceasefire plan for the Gaza Strip remain stalled, heightening fears of renewed fighting. Israel is insisting that Hamas hand ...

The KEYMAKER-U03 trial showed a triplet regimen of belzutifan, pembrolizumab, and lenvatinib significantly improved ...

Even as a U.S.–China trade truce appears to be holding, analysts caution that the détente remains fragile in a rivalry ...